FDA approval of EBGLYSS™ (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis in adults and children aged 12 and older

The Food and Drug Administration has approved EBGLYSS™ (lebrikizumab-lbkz) for the treatment of patients of moderate-to-severe atopic dermatitis (AD) (eczema) who weigh at least 88 pounds (40 kg). AD is a chronic, inflammatory, pruritic skin disorder affecting up to 20% of children and 3% of adults worldwide. Lebrikizumab, an interleukin-13 inhibitor, has shown promising results in improving symptoms, quality of life, and disease severity in patients with moderate-to-severe AD. Administered via subcutaneous injection, lebrikizumab offers rapid symptom relief with potentially lower systemic side effects compared to other therapies. However, the drug development process carries inherent risks and uncertainties. Overall, lebrikizumab represents a valuable option for patients with AD, potentially enhancing their quality of life and confidence.